Joseph R Osborne1,2, Teja M Kalidindi3, Blesida J Punzalan3, Kishore Gangangari4,5, Daniel E Spratt6, Wolfgang A Weber4, Steven M Larson4,7,3, Naga Vara Kishore Pillarsetty4,7,8. 1. Department of Radiology, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, Box 77, New York, NY, 10065, USA. osbornej@mskcc.org. 2. Department of Radiology, Weill Cornell Medical College, New York, NY, USA. osbornej@mskcc.org. 3. Molecular Pharmacology Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA. 4. Department of Radiology, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, Box 77, New York, NY, 10065, USA. 5. Department of Chemistry, Hunter College and PhD Program in Chemistry, The Graduate Center of the City University of New York, New York, NY, USA. 6. Department of Radiation Oncology, University of Michigan, Ann Arbor, MI, USA. 7. Department of Radiology, Weill Cornell Medical College, New York, NY, USA. 8. Department of Radiology, Memorial Sloan Kettering Cancer Center, Zuckerman Research Center, 417 East 68th Street, New York, NY, 10065, USA.
Abstract
PURPOSE: We studied the effect of varying specific activity of [68Ga]DKFZ-PSMA11 ([68Ga]DP11) on repeated imaging of prostate-specific membrane antigen-positive (PSMA+) xenograft tumors. PROCEDURES: Athymic nude mice bearing PC3-PIP (PSMA+) and PC3 (PSMA-) bilateral flank tumors were assessed to study intra- and inter-day repeatability of [68Ga]DP11 imaging in mice administered [68Ga]DP11 or [67Ga]DP11 (as a dilution tracer) using imaging and biodistribution studies. RESULTS: Region of interest (ROI) analysis of the [68Ga]DP11 imaging study indicated that the uptake was constant on the same day or consecutive days. Prior imaging with [68Ga]DP11 did not significantly influence the subsequent uptake of [68Ga]DP11. Uptake of [68Ga]DP11 (60 min) and [67Ga]DP11 (24 h) in PC3-PIP tumors was 12.37 ± 4.19 %ID/g and 12.49 ± 6.88 %ID/g, respectively; [68Ga]DP11 was 13.83 ± 3.77 and 17.76 ± 1.84 on same-day and 15.98 ± 5.82 %ID/g on second-day imaging. CONCLUSIONS: This study demonstrates that [68Ga]DP11, in a given PSMA+ lesion, is constant under several same-day or serial-day imaging conditions.
PURPOSE: We studied the effect of varying specific activity of [68Ga]DKFZ-PSMA11 ([68Ga]DP11) on repeated imaging of prostate-specific membrane antigen-positive (PSMA+) xenograft tumors. PROCEDURES: Athymic nude mice bearing PC3-PIP (PSMA+) and PC3 (PSMA-) bilateral flank tumors were assessed to study intra- and inter-day repeatability of [68Ga]DP11 imaging in mice administered [68Ga]DP11 or [67Ga]DP11 (as a dilution tracer) using imaging and biodistribution studies. RESULTS: Region of interest (ROI) analysis of the [68Ga]DP11 imaging study indicated that the uptake was constant on the same day or consecutive days. Prior imaging with [68Ga]DP11 did not significantly influence the subsequent uptake of [68Ga]DP11. Uptake of [68Ga]DP11 (60 min) and [67Ga]DP11 (24 h) in PC3-PIP tumors was 12.37 ± 4.19 %ID/g and 12.49 ± 6.88 %ID/g, respectively; [68Ga]DP11 was 13.83 ± 3.77 and 17.76 ± 1.84 on same-day and 15.98 ± 5.82 %ID/g on second-day imaging. CONCLUSIONS: This study demonstrates that [68Ga]DP11, in a given PSMA+ lesion, is constant under several same-day or serial-day imaging conditions.
Authors: Clemens Kratochwil; Frank Bruchertseifer; Frederik L Giesel; Mirjam Weis; Frederik A Verburg; Felix Mottaghy; Klaus Kopka; Christos Apostolidis; Uwe Haberkorn; Alfred Morgenstern Journal: J Nucl Med Date: 2016-07-07 Impact factor: 10.057
Authors: Ying Chen; Catherine A Foss; Youngjoo Byun; Sridhar Nimmagadda; Mrudula Pullambhatla; James J Fox; Mark Castanares; Shawn E Lupold; John W Babich; Ronnie C Mease; Martin G Pomper Journal: J Med Chem Date: 2008-12-25 Impact factor: 7.446
Authors: Neeta Pandit-Taskar; Joseph A O'Donoghue; Volkan Beylergil; Serge Lyashchenko; Shutian Ruan; Stephen B Solomon; Jeremy C Durack; Jorge A Carrasquillo; Robert A Lefkowitz; Mithat Gonen; Jason S Lewis; Jason P Holland; Sarah M Cheal; Victor E Reuter; Joseph R Osborne; Massimo F Loda; Peter M Smith-Jones; Wolfgang A Weber; Neil H Bander; Howard I Scher; Michael J Morris; Steven M Larson Journal: Eur J Nucl Med Mol Imaging Date: 2014-08-21 Impact factor: 9.236
Authors: P M Smith-Jones; S Vallabahajosula; S J Goldsmith; V Navarro; C J Hunter; D Bastidas; N H Bander Journal: Cancer Res Date: 2000-09-15 Impact factor: 12.701
Authors: Steve Y Cho; Kenneth L Gage; Ronnie C Mease; Srinivasan Senthamizhchelvan; Daniel P Holt; Akimosa Jeffrey-Kwanisai; Christopher J Endres; Robert F Dannals; George Sgouros; Martin Lodge; Mario A Eisenberger; Ronald Rodriguez; Michael A Carducci; Camilo Rojas; Barbara S Slusher; Alan P Kozikowski; Martin G Pomper Journal: J Nucl Med Date: 2012-12 Impact factor: 10.057
Authors: Martin A Lodge; Matthias Holdhoff; Jeffrey P Leal; Asim K Bag; L Burt Nabors; Akiva Mintz; Glenn J Lesser; David A Mankoff; Arati S Desai; James M Mountz; Frank S Lieberman; Joy D Fisher; Serena Desideri; Xiaobu Ye; Stuart A Grossman; David Schiff; Richard L Wahl Journal: J Nucl Med Date: 2016-09-29 Impact factor: 10.057
Authors: Edward K Fung; Sarah M Cheal; Shoaib B Fareedy; Blesida Punzalan; Volkan Beylergil; Jawaria Amir; Sandhya Chalasani; Wolfgang A Weber; Daniel E Spratt; Darren R Veach; Neil H Bander; Steven M Larson; Pat B Zanzonico; Joseph R Osborne Journal: EJNMMI Res Date: 2016-01-22 Impact factor: 3.138
Authors: Katharina Lückerath; Andreea D Stuparu; Liu Wei; Woosuk Kim; Caius G Radu; Christine E Mona; Jeremie Calais; Matthew Rettig; Robert E Reiter; Johannes Czernin; Roger Slavik; Ken Herrmann; Matthias Eiber; Wolfgang P Fendler Journal: J Nucl Med Date: 2018-03-30 Impact factor: 10.057